# Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study

> **NCT02472080** · PHASE2 · TERMINATED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 21 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** gemcitabine -oxaliplatine combination

## Key facts

- **NCT ID:** NCT02472080
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-07
- **Primary completion:** 2018-04-01
- **Final completion:** 2019-01-15
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** inefficiency
- **Last updated:** 2019-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02472080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02472080, "Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02472080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*